Gains in life expectancy from medical interventions

New England Journal of Medicine

Volumn 339, Issue 26, 1998, Pages 1943-1944

  Messori, Andrea ^a   Trippoli, Sabrina ^a   Tendi, Enrico ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

COST BENEFIT ANALYSIS; HUMAN; LIFE EXPECTANCY; NEOPLASM; NOTE; SURVIVAL; ATTITUDE TO HEALTH; HEALTH BEHAVIOR; INTERPERSONAL COMMUNICATION; MOTIVATION;

COST-BENEFIT ANALYSIS; HUMANS; LIFE EXPECTANCY; NEOPLASMS; SURVIVAL ANALYSIS; ATTITUDE TO HEALTH; COMMUNICATION; HEALTH BEHAVIOR; MOTIVATION;

EID: 0032564698     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199812243392616     Document Type: Article

References (4)

1. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996;276:1253-8.
2. Messori A, Trippoli S. Lifetime survival gain using streptokinase or TPA in acute myocardial infarction. (See: http://www.bmj.com/cgi/content/ abstract/316/7141/1337#responses.) (Also available from NAPS, c/o Microfiche Publications, P.O. Box 3513, Grand Central Station, New York, NY 10163-3513.)
3. Messori A, Becagli P, Trippoli S, Tendi E. A retrospective cost-effectiveness analysis of interferon as adjuvant therapy in high-risk resected cutaneous melanoma. Eur J Cancer 1997;33:1373-9.
4. Messori A. Cost-effectiveness of interferon in chronic myeloid leukaemia: analysis of four clinical studies. Ann Oncol 1998;9:389-96.